They are one of the dangerous drug in the market place.
With Omontys it is just the first day reaction and emphasized 25000 patients.
With Arsnep and Epo, it is not the case. One needs to monitor the patients all the time, very dangerous indeed.
Takeda addresses the first day issue on multiple fronts, gets the FDA nod and strictly enforces it, the Drug is back in the shelfs in no time.
Sentiment: Strong Buy